In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa
ABSTRACT Introduction Tenofovir disoproxil fumarate (TDF) is a common drug of choice for pre‐exposure prophylaxis (PrEP) or as a combination HIV treatment for pregnant women. In‐utero exposure to TDF was found to be associated with lower bone mineral content (BMC) in HIV‐exposed uninfected neonates....
Saved in:
| Main Authors: | Kerusha Reddy, Kimesh L. Naidoo, Carl Lombard, Zukiswa Godlwana, Alicia C. Desmond, Richard Clark, James F. Rooney, Glenda Gray, Dhayendre Moodley |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Journal of the International AIDS Society |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jia2.26379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Factors driving decisions in the use of HIV pre-exposure prophylaxis: a real-world study in the United States
by: Yohance Whiteside, et al.
Published: (2024-12-01) -
Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01) -
Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report
by: Ris Raihan Felim, et al.
Published: (2024-10-01) -
Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report
by: Ris Raihan Felim, et al.
Published: (2024-07-01) -
A cross‐sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV‐1 in tenofovir disoproxil fumarate‐based pre‐exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa
by: Urvi M. Parikh, et al.
Published: (2025-08-01)